- /
- Supported exchanges
- / US
- / ANIP.NASDAQ
ANI Pharmaceuticals Inc (ANIP NASDAQ) stock market data APIs
ANI Pharmaceuticals Inc Financial Data Overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ANI Pharmaceuticals Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ANI Pharmaceuticals Inc data using free add-ons & libraries
Get ANI Pharmaceuticals Inc Fundamental Data
ANI Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 827 M
- EBITDA: 146 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 1.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ANI Pharmaceuticals Inc News
New
ANIP Q3 Deep Dive: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations , with sales up 53.6% year on year to $227.8 million. The comp...
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance Biotherapeutics IOVA incurred a third-quarter 2025 loss of 25 cents per share, narrower than the Zacks Consensus Estimate of a loss of 29 cents. In the year-ago quarter, the company reported a...
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
Novavax NVAX incurred a loss of 62 cents per share in the third quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.08 per share. In the year-ago quarter, the company...
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion Therapeutics ESPR incurred a loss of 16 cents per share in the third quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 9 cents. The company had incurred a loss o...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.